➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
McKesson
Boehringer Ingelheim
Baxter

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for DS-5565

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for DS-5565?

DS-5565 is an investigational drug.

There have been 12 clinical trials for DS-5565. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Neuralgia, Diabetic Neuropathies, and Myofascial Pain Syndromes. The leading clinical trial sponsors are Daiichi Sankyo Co., Ltd., Daiichi Sankyo Inc., and INC Research.

There are eight US patents protecting this investigational drug and one hundred and thirty-seven international patents.

Recent Clinical Trials for DS-5565
TitleSponsorPhase
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic PainDaiichi Sankyo Co., Ltd.Phase 3
Study of Mirogabalin for Central Neuropathic PainDaiichi Sankyo Co., Ltd.Phase 3
DS-5565 Phase III Study for Renal Impairment in Japanese SubjectsCMIC Co, Ltd. JapanPhase 3

See all DS-5565 clinical trials

Clinical Trial Summary for DS-5565

Top disease conditions for DS-5565
Top clinical trial sponsors for DS-5565

See all DS-5565 clinical trials

US Patents for DS-5565

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DS-5565   Start Trial Solid preparation including antioxidant DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP)   Start Trial
DS-5565   Start Trial Bicyclic .gamma.-amino acid derivative Daiichi Sankyo Company, Ltd. (Tokyo, JP)   Start Trial
DS-5565   Start Trial Method for producing bicyclic .gamma.-amino acid derivative Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
DS-5565   Start Trial Methods for producing bicyclic compounds via claisen rearrangements Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
DS-5565   Start Trial Methods for producing bicyclic compounds via iminium salt Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
DS-5565   Start Trial Optical resolution methods for bicyclic compounds using enzymes DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DS-5565

Drugname Country Document Number Estimated Expiration Related US Patent
DS-5565 Brazil BR112017019918 2035-03-19   Start Trial
DS-5565 Canada CA2980096 2035-03-19   Start Trial
DS-5565 China CN107405322 2035-03-19   Start Trial
DS-5565 European Patent Office EP3272345 2035-03-19   Start Trial
DS-5565 Spain ES2766424 2035-03-19   Start Trial
DS-5565 Hong Kong HK1250013 2035-03-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
McKesson
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.